首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat.
【24h】

Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat.

机译:肾血管紧张素2型受体通过血管紧张素II 1型受体阻断的大鼠通过血管紧张素III介导利尿。

获取原文
获取原文并翻译 | 示例
       

摘要

Whereas angiotensin (Ang) II is the major effector peptide of the renin-angiotensin system, its metabolite, des-aspartyl1-Ang II (Ang III), may also have biologic activity. We investigated the effects of renal interstitial (RI) administration of candesartan (CAND), a specific Ang II type 1 receptor (AT1) blocker, with and without coinfusion of PD-123319 (PD), a specific Ang II type 2 receptor (AT2) blocker, on Na+ excretion (UNaV) in uninephrectomized rats. We also studied the effects of unilateral RI infusion of Ang II or Ang III on UNaV with and without systemic infusion of CAND with the noninfused kidney as control. In rats receiving normal Na+ intake, RI CAND increased UNaV from 0.07+/-0.08 to 0.82+/-0.17 micromol/min (P<0.01); this response was abolished by PD. During Na+ restriction, CAND increased UNaV from 0.06+/-0.02 to 0.1+/-0.02 micromol/min (P<0.05); this response also was blocked by PD. In rats with both kidneys intact, in the absence of CAND, unilateral RI infusion of Ang III did not significantly alter UNaV. However, with systemic CAND infusion, RI Ang III increased U(Na)V from 0.08+/-0.01 micromol/min to 0.18+/-0.04 micromol/min (P<0.01) at 3.5 nmol/kg per minute, and UNaV remained elevated throughout the infusion; this response was abolished by PD. However, RI infusion of Ang II did not significantly alter UNaV at any infusion rate (3.5 to 80 nmol/kg per minute) with or without systemic CAND infusion. These results suggest that intrarenal AT1 receptor blockade engenders natriuresis by activation of AT2 receptors. AT2 receptor activation via Ang III, but not via Ang II, mediates the natriuretic response in the presence of systemic AT1 receptor blockade.
机译:血管紧张素(Ang)II是肾素-血管紧张素系统的主要效应肽,而其代谢产物des-aspartyl1-Ang II(Ang III)也可能具有生物活性。我们调查了坎地沙坦(CAND)(一种特定的Ang II 1型受体(AT1)阻断剂)在肾间质(RI)给药中是否与PD-123319(PD),一种特定的Ang II 2型受体(AT2)共融合的影响)阻滞剂,用于未切除卵的大鼠的Na +排泄(UNaV)。我们还研究了单侧RI输注Ang II或Ang III对UNaV的影响,无论是否使用全身输注CAND以及未输注肾脏作为对照。在接受正常Na +摄入的大鼠中,RI CAND将UNaV从0.07 +/- 0.08微摩尔/分钟增加到0.82 +/- 0.17微摩尔/分钟(P <0.01); PD取消了此响应。在Na +限制期间,CAND将UNaV从0.06 +/- 0.02微摩尔/分钟增加到0.1 +/- 0.02微摩尔/分钟(P <0.05); PD也阻止了此响应。在没有CAND的情况下,两个肾脏都完整的大鼠中,单侧RI输注Ang III不会显着改变UNaV。但是,通过全身性CAND输注,RI Ang III将U(Na)V从0.08 +/- 0.01 micromol / min增加到0.18 +/- 0.04 micromol / min(P <0.01),流速为3.5 nmol / kg /分钟,并且仍保留UNaV在整个输注过程中升高; PD取消了此响应。但是,在有或没有全身性CAND输注的情况下,在任何输注速率(3.5至80 nmol / kg每分钟)下,RI Ang II输注都不会显着改变UNaV。这些结果表明,肾内AT1受体的阻断通过激活AT2受体而引起钠尿。在存在全身性AT1受体阻滞剂的情况下,通过Ang III而不是通过Ang II的AT2受体激活介导了利钠尿反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号